福元医药：坎地沙坦酯氢氯噻嗪片（Ⅱ）获得药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical (601089) has received the drug registration certificate from the National Medical Products Administration for Candesartan Cilexetil and Hydrochlorothiazide Tablets, indicating a significant step in expanding its product portfolio in the hypertension treatment market [1] Group 1: Product Approval - The approved product is Candesartan Cilexetil and Hydrochlorothiazide Tablets, with each tablet containing 16mg of Candesartan Cilexetil and 12.5mg of Hydrochlorothiazide [1] - This medication is not intended for initial treatment of hypertension but is suitable for adults with primary hypertension who do not achieve effective blood pressure control with either Candesartan Cilexetil or Hydrochlorothiazide alone [1] - The drug can also serve as a replacement therapy for patients already on a combination of both medications at the same dosage [1]